The agency’s emergency committee met Oct. 20 to discuss the state of the monkeypox outbreak, which has infected more than 77,000 people globally, CDC data shows.
In a Nov. 1 statement on the meeting, the WHO’s emergency committee cited ongoing transmission in certain regions, the ongoing risk of stigma and discrimination, potential case underreporting in some developing countries, and a lack of equitable access to vaccines and treatments as the primary reasons for ongoing international concern.
They also acknowledged progress that has been made to slow the outbreak, such as increased vaccine uptake and behavioral changes.
“Nonetheless, the picture is mixed,” the group said, referring to the range in countries’ progress at curbing the outbreak. While the group currently deems the public health risk moderate globally, it’s considered high in the Americas. Monkeypox was first deemed a global public health emergency July 23.
In the U.S., 28,442 cases had been confirmed as of Nov. 1. A recent CDC report found the majority of monkeypox patients in the U.S. who developed illness that required hospitalization had weakened immune systems, often from HIV.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
